


CM

We claim:

1. A compound of formula (I)

5

16310X



(I)

PS 10 wherein

PS 15  $R_1$  represents a hydrogen atom or a  $C_{1-6}$  alkyl group;

$R_2$  represents a hydrogen atom or a  $C_{1-6}$  alkyl group;

$R_3$  represents a hydrogen atom;

$R_4$  represents a hydrogen atom or a  $C_{1-3}$  alkyl group;

PS 15 *or a* and pharmaceutically acceptable salts and solvates thereof.

2. A compound according to Claim 1 wherein in the formula (I)  $R_1$  represents a hydrogen atom or a  $C_{1-3}$  alkyl group.

20 3. A compound according to Claim 1 wherein in the formula (I)  $R_2$  represents a hydrogen atom or a  $C_{1-3}$  alkyl group.

4. A compound according to Claim 1 wherein in the formula (I)  $R_2$  represents a  $C_{1-3}$  alkyl group.

25

5. A compound according to Claim 1 wherein in the formula (I)  $R_4$  represents a  $C_{1-3}$  alkyl group.

30

6. N-Methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

35

7. N,N-Dimethyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

8. N-Ethyl-3-(4-piperidinyl)-1H-indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

5 9. N-Methyl-3-(4-piperidinyl)-1H-indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

10 10. 3-(1-Methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide and pharmaceutically acceptable salts and solvates thereof.

15 11. A pharmaceutical composition which comprises an effective amount of at least one compound of formula (I) as defined in Claim 1 or a pharmaceutically acceptable salt or solvate thereof together with one or more pharmaceutically acceptable carriers or excipients.

133 12. A pharmaceutical composition according to Claim 11 adapted for oral, parenteral or intranasal administration.

144 20 13. A pharmaceutical composition according to Claim 11 which is formulated in unit dosage form comprising 0.1mg to 100mg of active ingredient.

15 25 14. A pharmaceutical composition according to Claim 12 which is formulated in unit dosage form comprising 0.1mg to 100mg of active ingredient.

16 30 15. A method of treating a human susceptible to or suffering from migraine cluster headache, chronic paroxysmal hemicrania or headache associated with vascular disorders which comprises administering an effective amount of a compound of formula (I) as defined in Claim 1 or a pharmaceutically acceptable salt or solvate thereof.

17 35 16. A method of treating a human susceptible to or suffering from migraine, cluster headache, chronic paroxysmal hemicrania or headache associated with vascular disorders which comprises administering a pharmaceutical composition according to Claim 11.


18. A method of treating a human susceptible to or suffering from migraine, cluster headache, chronic paroxysmal hemicrania or headache associated with vascular disorders which comprises administering a pharmaceutical composition according to Claim 12. 13

5

18. A compound of formula (II)

10

$R_1 R_2 NSO_2 (CH_2)_2$




(II)

15

wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are as defined in Claim 1.

20

$HOSO_2 (CH_2)$




(V)

25

wherein  $R_3$  and  $R_4$  are as defined in Claim 1

30

$R_1 R_2 NSO_2 CH=CH$



(X)

35

wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are as defined in Claim 1.

add A1  
add B2